Wall Street brokerages expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to announce earnings per share (EPS) of ($0.18) for the current quarter, Zacks reports. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.17). Achillion Pharmaceuticals posted earnings of ($0.15) per share during the same quarter last year, which would indicate a negative year over year growth rate of 20%. The firm is expected to announce its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.66) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.57). For the next year, analysts forecast that the company will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.82) to ($0.61). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.16). During the same quarter in the prior year, the firm posted ($0.14) EPS.

A number of brokerages have recently weighed in on ACHN. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. ValuEngine lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Finally, Robert W. Baird lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Achillion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.75.

COPYRIGHT VIOLATION NOTICE: “-$0.18 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/06/0-18-eps-expected-for-achillion-pharmaceuticals-inc-achn-this-quarter.html.

Achillion Pharmaceuticals (NASDAQ ACHN) traded up 1.06% during trading on Friday, hitting $4.76. 1,005,429 shares of the stock were exchanged. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $7.98. The stock’s market cap is $650.98 million. The stock has a 50 day moving average of $4.48 and a 200-day moving average of $4.22.

Large investors have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. boosted its stake in Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 4,144 shares in the last quarter. TradeLink Capital LLC bought a new position in shares of Achillion Pharmaceuticals in the second quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Achillion Pharmaceuticals in the first quarter worth approximately $138,000. Finally, Highbridge Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals in the first quarter worth approximately $149,000. 74.11% of the stock is currently owned by institutional investors and hedge funds.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.